DOI: 10.1128/AAC.00340-15
Article Information
PubMed
Published By
History
- Received February 10, 2015
- Returned for modification March 20, 2015
- Accepted March 29, 2015
- Published online May 14, 2015.
Copyright & Usage
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (April 06, 2015).
- You are viewing the most recent version of this article.
Author Information
- Daniel S. Steina,
- Jay Prakash Jainb,
- Michael Kangasc,
- Gilbert Lefèvrec,
- Surendra Machinenid,
- Paul Griffine and
- Jason Lickliterf
- aNovartis Institute for BioMedical Research, East Hanover, New Jersey, USA
- bNovartis Institute for BioMedical Research, Hyberabad, India
- cNovartis Institute for BioMedical Research, Basel, Switzerland
- dIntegrated Quantitative Sciences, Hyderabad, India
- eQ-Pharm Pty. Ltd., QIMR Berghofer Medical Research Institute, Mater Health Services and Mater Research, and the University of Queensland, Brisbane, Queensland, Australia
- fNucleus Network Ltd., Melbourne, Victoria, Australia
- Address correspondence to Daniel S. Stein, daniel.stein{at}novartis.com.
Citation Stein DS, Jain JP, Kangas M, Lefèvre G, Machineni S, Griffin P, Lickliter J. 2015. Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine. Antimicrob Agents Chemother 59:3493–3500. doi:10.1128/AAC.00340-15.
